Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MTHFR risk alleles associate with Th17 immunity and spinal damage in axial spondyloarthritis.

Clinical immunology (Orlando, Fla.)·2026
Same author

Interplay of steric hindrance and electronic effects in asymmetric diglycolamides revealed through their Ln(III) coordination and extraction behavior.

Dalton transactions (Cambridge, England : 2003)·2026
Same author

Evaluating the role of serum IL1R2 as a biomarker for diagnosis and prognostic stratification in sepsis.

European journal of medical research·2026
Same author

Two-Dimensional La<sub>2</sub>CoO<sub>4</sub> Perovskite Oxide Enabled by Phonon-Resonance-Driven Exfoliation for High-Performance Gas Sensing.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

CD2 targeted nanoparticles containing IL-2 mimic fetal-maternal tolerance of pregnancy by inducing synergistic TGF-β-producing NK cells and Tregs.

Frontiers in immunology·2025
Same author

Interactions between Methyl Branched-Chain Asymmetric Diglycolamides and Ln<sup>3+</sup>: Extraction and Spectroscopic and Theoretical Investigations.

Inorganic chemistry·2025

Related Experiment Video

Updated: May 26, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Targeting BLyS in systemic lupus erythematosus.

Yaoyang Liu1, Antonio La Cava

  • 1Department of Medicine of the University of California Los Angeles, 1000 Veteran Avenue 32-59, Los Angeles, California 90095-1670, USA.

Recent Patents on Inflammation & Allergy Drug Discovery
|January 6, 2012
PubMed
Summary

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Targeting B-cell growth factor BLyS with belimumab offers a new therapeutic option for SLE patients, addressing a critical need for effective treatments.

More Related Videos

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Related Experiment Videos

Last Updated: May 26, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Systemic lupus erythematosus (SLE) is a disabling autoimmune disease impacting patient quality of life and longevity.
  • B-cell autoantibody production is central to SLE pathogenesis.
  • B lymphocyte stimulator (BLyS) is crucial for B-cell development and survival, making it a key therapeutic target.

Purpose of the Study:

  • To review the targeting of BLyS in SLE animal models.
  • To examine the clinical use of belimumab in human SLE.
  • To discuss relevant patents concerning BLyS inhibition in SLE.

Main Methods:

  • Review of preclinical studies in lupus animal models investigating BLyS inhibition.
  • Analysis of clinical trial data and real-world evidence for belimumab in SLE patients.
  • Survey of patent literature related to BLyS-targeting therapies for SLE.

Main Results:

  • BLyS targeting has shown efficacy in lupus animal models.
  • Belimumab, a neutralizing anti-BLyS monoclonal antibody, is FDA-approved for SLE treatment.
  • This represents a significant advancement after decades without new SLE drug approvals.

Conclusions:

  • Targeting BLyS is a validated therapeutic strategy for SLE.
  • Belimumab provides a novel treatment option for patients with SLE.
  • Further research and patenting activity are expected in this area.